表紙
市場調查報告書

老年癡呆症:開發平台分析

Alzheimer's Disease - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232776
出版日期 內容資訊 英文 1716 Pages
訂單完成後即時交付
價格
老年癡呆症:開發平台分析 Alzheimer's Disease - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 1716 Pages
簡介

老年癡呆症,是進行性且慢慢症狀惡化的疾病,神經受侵襲而發生記憶和行動障礙。 神經進行信號傳送的神經傳達物質乙醯膽鹼的合成,受破壞的話信號傳達斷絕最終記憶和行動功能產生障礙。年齡、遺傳、循環系統疾病、糖尿病、環境的要素等,各式各樣的因素讓老年癡呆症發病的風險高漲。也有引起各種併發症的情況,不進行治療的話也可能致命。

本報告提供老年癡呆症的治療藥開發平台的現狀及最新更新的各開發階段比較分析,企業和研究機關開發中的治療藥,治療藥的評估,後期階段及中止的計劃相關資訊等最新新聞和發表。

簡介

  • 老年癡呆症 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11975IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2020, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 20, 64, 74, 4, 320, 129 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 3, 100 and 45 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Alzheimer's Disease - Overview
  • Alzheimer's Disease - Therapeutics Development
  • Alzheimer's Disease - Therapeutics Assessment
  • Alzheimer's Disease - Companies Involved in Therapeutics Development
  • Alzheimer's Disease - Drug Profiles
  • Alzheimer's Disease - Dormant Projects
  • Alzheimer's Disease - Discontinued Products
  • Alzheimer's Disease - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Alzheimer's Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..11), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..12), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..13), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..14), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..15), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..16), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..17), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..18), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..19), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..20), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..11), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..12), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..13), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..14), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..15), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..16), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..17), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..18), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..19), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..20), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..21), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..22), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..23), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..24), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..25), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..26), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..27), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..28), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..29), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..30), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..31), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..32), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..2), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..4), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..5), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..6), H1 2020
  • Products under Development by Universities/Institutes, H1 2020 (Contd..7), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..7), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..8), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..9), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..10), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..6), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..7), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..8), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..9), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..10), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Alzheimer's Disease - Pipeline by 1st Bio Therapeutics Inc, H1 2020
  • Alzheimer's Disease - Pipeline by 2A Pharma AB, H1 2020
  • Alzheimer's Disease - Pipeline by 4D Pharma Plc, H1 2020
  • Alzheimer's Disease - Pipeline by 4P-Pharma SAS, H1 2020
  • Alzheimer's Disease - Pipeline by AB Science SA, H1 2020
  • Alzheimer's Disease - Pipeline by Abaxy Sprl, H1 2020
  • Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2020
  • Alzheimer's Disease - Pipeline by AC Immune SA, H1 2020
  • Alzheimer's Disease - Pipeline by Acelerox LLC, H1 2020
  • Alzheimer's Disease - Pipeline by Acelot Inc, H1 2020
  • Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2020
  • Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2020
  • Alzheimer's Disease - Pipeline by AcuraStem Inc, H1 2020
  • Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2020
  • Alzheimer's Disease - Pipeline by Adocia SAS, H1 2020
  • Alzheimer's Disease - Pipeline by ADRx Inc, H1 2020
  • Alzheimer's Disease - Pipeline by Aerobyx LLC, H1 2020
  • Alzheimer's Disease - Pipeline by AfaSci Inc, H1 2020
  • Alzheimer's Disease - Pipeline by Affichem SA, H1 2020
  • Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2020
  • Alzheimer's Disease - Pipeline by Aibios Co Ltd, H1 2020
  • Alzheimer's Disease - Pipeline by Alector Inc, H1 2020

List of Figures

  • Number of Products under Development for Alzheimer's Disease, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020